-+ 0.00%
-+ 0.00%
-+ 0.00%

Stocks in play: Oncolytics Biotech Inc

Barchart·08/18/2026 08:57:00
Listen to the news

Announces it has received written feedback from the U.S. Food and Drug Administration regarding the design of a potential pivotal Part B expansion of REO 033, the Company’s ongoing randomized study evaluating pelareorep in second-line RAS-mutant, microsatellite stable metastatic colorectal cancer. Oncolytics Biotech Inc shares N.ONCY are trading up one cent at $0.83.

Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=4568478878479694